Cell Therapy Manufacturing Market (2017-2027): Near-Term Demand Driven by Clincial Candidates - Research and Markets

News provided by

Mar 24, 2017, 10:15 ET

DUBLIN, Mar 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cell Therapy Manufacturing Market, 2017-2027" report to their offering.

The Cell Therapy Manufacturing Market, 2017-2027 report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. These therapies are anticipated to emerge as viable alternatives to conventional treatment options.

The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand.

Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.

The near-term demand for manufacturing of cell-based therapies will primarily be driven by clinical candidates. In the longer term, the currently approved therapies and late-stage therapies (that are likely to get commercialized in future) will act as key drivers of the market. Our outlook is highly promising; we expect the market for cell therapy manufacturing to grow at an annualized growth rate of -42% over the course of next ten years and be worth over USD 4 billion in 2027.

Companies Mentioned

3P Biopharmaceuticals
A2 Healthcare
Abramson Cancer Center
Adaptimmune
Adicet Bio
Advanced Manufacturing Technologies (AMTech)
Alberta Cell Therapy Manufacturing
Allele Biotechnology and Pharmaceuticals
Alliance for Regenerative Medicine
AlloSource
Altor BioScience
American Society of Gene and Cell Therapy
(300+ Others)

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. CELL THERAPY MANUFACTURING: INTRODUCTION

4. MARKET OVERVIEW

5. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES

6. CELL THERAPY MANUFACTURING: IN-HOUSE MANUFACTURERS

7. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS

8. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS

9. ROLE OF NON-PROFIT ORGANIZATIONS

10. RECENT DEVELOPMENTS

11. MARKET SIZING AND FORECAST

12. SWOT ANALYSIS

13. CONCLUSION

14. SURVEY ANALYSIS

15. INTERVIEW TRANSCRIPT

For more information about this report visit http://www.researchandmarkets.com/research/z9w7mt/cell_therapy

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets